SAB Biotherapeutics, Inc. SABS
We are a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. Our programs are based on mechanisms of action that have achieved proof-of-concept in clinical trials in indications with significant unmet medical needs. We are focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. The Company's lead candidate, SAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach that aims to potentially change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $1.3M | $2.2M | $23.9M | $60.9M | $55.2M | — |
| R&D | $34.4M | $30.3M | $16.5M | $36.4M | $57.2M | $27.9M | — |
| SG&A | $14.6M | $14.0M | $23.8M | $16.4M | $17.1M | $6.8M | — |
| Total operating expenses | $49.0M | $44.2M | $40.3M | $52.8M | $74.3M | $34.7M | — |
| Operating income | -$49.0M | -$42.9M | -$38.1M | -$28.9M | -$13.4M | $20.6M | — |
| Interest expense | $240.7K | $318.4K | $315.3K | $301.6K | $294.5K | $469.2K | — |
| Pre-tax income | $13.3M | -$34.1M | -$42.2M | -$18.7M | -$17.1M | $20.1M | — |
| Income tax | $0 | $0 | $0 | $25.6K | $0 | $0 | — |
| Net income | $13.3M | -$34.1M | -$42.2M | -$18.7M | -$17.1M | $20.1M | — |
| EPS, basic | 0.22 | -3.68 | -7.64 | -4.31 | -0.63 | 0.79 | — |
| EPS, diluted | -0.79 | -3.68 | -7.64 | -4.31 | -0.63 | 0.74 | — |
| Shares, diluted (wtd. avg.) | 61.3M | 9.3M | 5.5M | 4.4M | 27.3M | 27.0M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $10.5M | $8.9M | $56.6M | $15.0M | $33.2M | $12.6M | — |
| Short-term investments | $86.1M | $11.9M | $0 | — | — | — | — |
| Receivables | — | — | $0 | $5.6M | $8.0M | $20.6M | — |
| Total current assets | $101.1M | $23.8M | $58.9M | $22.1M | $50.2M | $34.5M | — |
| Property, plant and equipment | $13.3M | $15.4M | $19.7M | $23.3M | $24.3M | $14.8M | — |
| Total assets | $172.8M | $44.2M | $83.9M | $50.9M | $81.1M | $56.5M | — |
| Accounts payable | $3.1M | $1.7M | $945.9K | $3.7M | $4.5M | $7.4M | — |
| Total current liabilities | $10.7M | $8.0M | $10.8M | $15.0M | $26.5M | $11.1M | — |
| Total liabilities | $21.3M | $18.2M | $26.6M | $19.8M | $42.6M | $17.5M | — |
| Retained earnings | -$110.9M | -$124.2M | -$90.1M | -$47.9M | -$29.1M | -$12.0M | — |
| Total equity | $151.5M | $26.0M | $57.3M | $31.1M | $38.5M | $39.0M | $7.7M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$44.8M | -$34.3M | -$25.1M | -$23.5M | $2.0M | $10.0M | — |
| Depreciation and amortisation | $3.0M | $4.7M | $3.7M | $3.2M | $1.5M | $383.1K | — |
| Stock-based compensation | $5.2M | $2.9M | $2.4M | $2.7M | $2.3M | $1.3M | — |
| Capital expenditure | $933.2K | $337.3K | $197.2K | $2.2M | $10.9M | $12.7M | — |
| Investing cash flow | -$121.7M | -$12.0M | -$152.7K | -$2.1M | -$10.9M | -$12.7M | — |
| Financing cash flow | $168.3M | -$1.2M | $66.8M | $1.1M | $35.9M | $9.0M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001833214-26-000003.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $55.2M | $60.9M | $23.9M | $2.2M | $1.3M | $0 |
| Gross profit | — | — | — | — | — | — | — |
| Net income | — | $20.1M | -$17.1M | -$18.7M | -$42.2M | -$34.1M | $13.3M |
Recent filings and events
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Regulation FD disclosure Item 7.01
- Material agreement signed Item 1.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Regulation FD disclosure Item 7.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Regulation FD disclosure Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |